Navigation Links
Trius Raises $30 Million in Series B Financing
Date:3/23/2008

Kleiner Perkins Makes First Investment in Antibacterial Therapeutics From

its Biodefense and Pandemic Fund

SAN DIEGO, March 24 /PRNewswire/ -- Trius Therapeutics, Inc. today announced the close of a $30 million Series B financing to advance the clinical development of its best-in-class oxazolidinone antibacterial drug TR-701, now completing Phase I testing. The financing was led by Kleiner, Perkins, Caufield and Byers (KPCB). New investor FinTech Global Capital participated in the round, along with all existing investors -- Sofinnova Ventures, Versant Ventures, Interwest Partners and Prism VentureWorks.

"The excellent results from our ongoing Phase I trial, including data confirming the potential for once-daily dosing, prompted us to raise this round of financing earlier than initially planned to accelerate the clinical development of TR-701," stated Jeffrey Stein, Ph.D., President and CEO of Trius Therapeutics. "We are encouraged that KPCB has recognized our potential and joined our strong investor group. The proceeds from this financing will enable Trius to advance TR-701 through Phase II and into Phase III development, and to continue to invest in our pre-clinical programs."

In connection with the Series B investment, KPCB partner Risa Stack, Ph.D. will join the Trius board. "Trius represents our first investment in an antibacterial therapeutics company out of our Biodefense and Pandemic Fund" said Dr. Stack. "It signifies not only our confidence in the Trius programs and management, but also our concern over the growing unmet need for effective new antibacterial therapies."

About Trius Therapeutics

Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by resistant pathogens. The company's lead drug candidate, TR-701 is a novel, oral and IV, oxazolidinone antibiotic with potent activity against drug-resistant Gram-positive bacterial path
'/>"/>

SOURCE Trius Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Alseres Pharmaceuticals, Inc. Raises $5 Million
2. Two Parents With Alzheimers Raises Childs Risk
3. Oregon study raises questions on synthetic progestins
4. Childrens Burn Foundations Benefit Raises More Than $875,000 for Burn Survivors and Prevention
5. Harley-Davidson Womens Day Ride Raises Funds for MDAs Summer Camp Program
6. Clinical depression raises risk of death for heart attack patients years after attack
7. Spanking Raises Chances of Risky, Deviant Sexual Behavior
8. Drug for anemic cancer patients raises risk of death
9. Lotus Pharmaceuticals Raises $5 Million in Private Placement
10. Guatemalas Fundacion Ayudame a Vivir Fundraising Campaign Raises More Than $2.6 Million
11. Blunt Praises Presidents Plan to Save Medicare
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)... CA (PRWEB) August 30, 2014 According ... upheld a decision that requires Takeda Pharmaceutical Co. and ... punitive damages for claims that the drugmakers concealed information ... diabetes medication Actos. The case, Allen v. Takeda Pharmaceuticals ... District Court, Western District of Louisiana (Lafayette).* , According ...
(Date:8/30/2014)... 2014 United Theological Seminary is pleased to ... the Master of Theological Studies (MTS). , ... designed for students who wish to pursue further academic study ... to serve the Church and community. Previously, students needed to ... can attend classes from any location where there is an ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 Daily Gossip ... that keeps anxiety and panic attacks under control with ... Away" program review describes this new method as ... control panic attacks and overcome general anxiety related disorders. ... successful is the fact that it can be accessed ...
(Date:8/30/2014)... RB SEO Services, a well-recognized internet marketing ... businesses. , RBSEO Services knows this very well that ... optimization service. So, the company has introduced this service, ... , On being asked about the service, a senior ... SEO service because many small businesses expressed their inability ...
(Date:8/30/2014)... 2014 Acne is a common problem millions of ... nothing more than a daily nuisance, for some, it can have ... acne can even lead to dramatic mood swings and depression. ... to clear up their skin. In some cases, that can make ... trial and error, those on a quest for clearer skin can ...
Breaking Medicine News(10 mins):Health News:The Law Office of Melinda J. Helbock A.P.C. Comments on Decision to Uphold $9 Billion Actos Award 2Health News:United Theological Seminary Announces First Fully Online Degree 2Health News:Panic Away Review Reveals New Natural Remedy for Anxiety Patients 2Health News:RBSEO Services Introduces Low Cost SEO Service for Small Businesses 2Health News:Acne Treatment Reviews Added to Popular Treatment Website 2
... May 8 Large rallies in,Northern and ... a three-day,statewide unfair labor practice strike by ... medical facilities that succeeded in raising public,awareness ... Inter-Con,Security., (Photo: http://www.newscom.com/cgi-bin/prnh/20080508/DC21718 ), ...
... (May 8, 2008, Toronto, ON) Women suffering with ... psychotherapy from a specially trained nurse over the phone, ... the availability of a psychologist or psychiatrist. , Dr. ... at the Lawrence S. Bloomberg Faculty of Nursing, University ...
... ROTTERDAM, Netherlands, May 8 LyondellBasell Industries,has ... (HACCP),certification of its management systems at its ... where MonoPropyleneGlycol USP/EP,(MPG-USP/EP) is produced., HACCP ... on preventing,food safety hazards. The comprehensive nature ...
... 8 Covance Inc. (NYSE:,CVD) today announced that it ... "We are very pleased to have Joe Scodari ... 34-year career as a key leader in the,pharmaceutical and ... driving growth in large, complex global healthcare businesses,",said Joe ...
... lead to new, genetically targeted therapies , , ... about the molecular mechanisms that cause cardiac arrhythmia ... death has been uncovered by Rhode Island Hospital ... to the development of new, genetically targeted therapies ...
... INETICO, Inc. and TPABenefits, Inc.,of San Antonio, ... interface,between the INETICO system and the TPABenefits Web ... Claims Management, Pre-Certification,and Wellness data source and allows ... Pre-Certifications and Case Notes on the,TPABenefits Web Portal., ...
Cached Medicine News:Health News:Three-Day Strike by Hundreds of Security Officers at Kaiser Hospitals Succeeds in Raising Red Flag About Unfair Labor Practices 2Health News:Three-Day Strike by Hundreds of Security Officers at Kaiser Hospitals Succeeds in Raising Red Flag About Unfair Labor Practices 3Health News:Raising the Bar on MonoPropyleneGlycol USP/EP 2Health News:Covance Elects Joseph C. Scodari to Company's Board of Directors 2Health News:Study Offers Clues to Link Between Arrhythmia, Sudden Death 2Health News:INETICO, Inc. Creates Data Interface with TPABenefits, Inc. Offering a Powerful Care and Claims Management Solution 2
(Date:8/29/2014)... August 29, 2014 According ... Product & Services (Equipment, Reagent, Primer, Probe, Custom ... PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) - ... global Oligonucleotide Synthesis Market is expected to reach ... 2014, growing at a CAGR of 9.8% from ...
(Date:8/29/2014)... 29, 2014  In part four of ... hospital pharmacy as a strategic asset, Mary Baxter, ... for Cardinal Health,s Innovation Delivery Solutions business, discusses how ... both hospitals and patients. "Every hospital pharmacist ... of their job in a value-based healthcare world," Baxter ...
(Date:8/29/2014)... -- Research and Markets  has announced the addition ... Market 2014-2018" report to their offering. ... that connect, support, or surround bones. There are several ... cartilage, fascia, and other fibrous tissues. Repetitive use, accidents, ... result in wear and tear in these tissues. Orthopedic ...
Breaking Medicine Technology:Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 2Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 3Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 4Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 3
... Phosphagenics,Limited (ASX: POH, AIM: PSG, OTCQX: PPGNY) today ... undertake a Phase 1 transdermal,oxycodone clinical trial aimed ... management product. Phosphagenics has submitted all necessary ... be conducted at CMAX - an independent clinical ...
... Phase 2 clinical development, PRINCETON, N.J., Sept. ... in the discovery and development of novel,small molecule ... 2a,clinical study of PS433540, the company,s lead internal ... receptor antagonist,(DARA) that is being developed as a ...
Cached Medicine Technology:Phosphagenics to Conduct a Phase 1 Transdermal Oxycodone Clinical Trial 2Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 2Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 3Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 4Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 5
... A biopsy with the MAMMOTOME® ... effective, minimally invasive procedure using ... management.,Using computer-generated images to locate ... accurately pinpoint and map the ...
... SEAMGUARD® Staple Line Reinforcement Material is ... postoperative pulmonary air leaks and as ... This inert, biocompatible, ePTFE material requires ... easy to load and fire and ...
... for the repair of abdominal hernias. It ... two distinct sides. One side of ... of sodium hyaluronate and carboxymethylcellulose (similar to ... side is bioresorbable, providing a temporary physical ...
... The Hernia Repair Company, we recognize that ... limited fibrous tissue in-growth between the prosthesis ... polypropylene mesh. Like all the products in ... produces a clinically proven, versatile repair.,The Reconix ...
Medicine Products: